EMA/718673/2012

European Medicines Agency decision

P/0274/2012

of 21 November 2012

on the acceptance of a modification of an agreed paediatric investigation plan for nilotinib (Tasigna) (EMEA-000290-PIP01-08-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

7 Westferry Circus ● Canary Wharf ● London E14 4HB ● United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

European Medicines Agency decision
P/0274/2012

of 21 November 2012

on the acceptance of a modification of an agreed paediatric investigation plan for nilotinib (Tasigna) (EMEA-000290-PIP01-08-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/60/2009 issued on 27 March 2009,

Having regard to the application submitted by Novartis Europharm Ltd on 13 July 2012 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 5 October 2012, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for nilotinib (Tasigna), capsule, hard, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Novartis Europharm Ltd, Wimblehurst Road, RH12 5AB Horsham, West Sussex, United Kingdom.

Done at London, 21 November 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/PDCO/572885/2012

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000290-PIP01-08-M02

Scope of the application

Active substance(s):

Nilotinib

Invented name:

Tasigna

Condition(s):

Treatment of chronic myeloid leukaemia

Treatment of gastro-intestinal stromal tumour

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Capsule, hard

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Novartis Europharm Ltd

Information about the authorised medicinal product:

See Annex II

7 Westferry Circus • Canary Wharf • London E14 4HB • United Kingdom
Telephone +44 (0)20 7418 8400 **Facsimile** +44 (0)20 7523 7040
E-mail info@ema.europa.eu **Website** www.ema.europa.eu

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Novartis Europharm Ltd submitted to the European Medicines Agency on 13 July 2012 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/60/2009 issued on 27 March 2009.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 9 August 2012.

Scope of the modification

Details of the studies and timelines were modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 5 October 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of gastro-intestinal stromal tumour

The waiver applies to:

- All subsets of the paediatric population from birth to less than 18 years of age
- for capsule, hard for oral use
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of chronic myeloid leukaemia

2.1.1. Indication(s) targeted by the PIP

Treatment of Philadelphia chromosome-positive chronic myeloid leukaemia.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years.

2.1.3. Pharmaceutical form(s)

Capsule, 200 mg and 50 mg, unmanipulated or contents dispersed with yoghurt or apple sauce, oral use.

2.1.4. Studies

Area	Number of studies	Description
Quality		Not applicable.
Non-clinical	1	Oral (gavage) juvenile development study in rats.
Clinical	3	Study to compare the bioavailability of nilotinib when administered as intact capsule or the capsule content mixed with yogurt or apple sauce in adult volunteers. Multiple-dose, open-label, single-agent, non-controlled trial to evaluate pharmacokinetics, pharmacodynamics, safety and activity in paediatric patients from birth to less than 18 years with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic or accelerated phase who are imatinib- and/or dasatinib-intolerant or in whom the disease is imatinib- and / or dasatinib-resistant, or with refractory or relapsed Philadelphia chromosome-positive acute lymphoblastic leukaemia. Multiple-dose, open-label, single-agent, non-controlled, multi-centre trial to evaluate pharmacokinetics, safety and activity in paediatric patients from birth to less than 18 years with Philadelphia chromosome-positive chronic myeloid leukaemia in chronic or accelerated phase who are imatinib- or dasatinib-intolerant or in whom the disease is imatinib- or dasatinib-resistant or with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By September 2015
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of chronic myeloid leukaemia

   Authorised indications:

   Tasigna is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase.

   Tasigna is indicated for the treatment of adult patients with:

   - newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase;
   - chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available.

Authorised pharmaceutical formulation(s):

Capsule, hard

Authorised route(s) of administration:

Oral use